An advisory committee to the Food and Drug Administration (FDA) has voted to recommend the inclusion of two peptides, BP-157 and KPV, on a list of approved drug substances for compounding pharmacies. The vote on July 23, which saw eight members in favor, six against, and one abstention for BP-157, signals a potential shift in how these substances are accessed, despite the FDA's documented opposition.
BP-157 is a synthetic peptide often explored for its potential in treating ulcerative colitis, while KPV is used for inflammatory conditions. The committee's decision means these peptides could be legally dispensed by compounding pharmacies. The vote occurred during a meeting where the committee considered whether compounding pharmacies could legally dispense certain peptides.
Proponents of the decision, including committee members with ties to telehealth companies, argued that allowing compounding pharmacies to dispense peptides would be safer than the current